Learn how Volv Global uses AI to study rare and complex diseases—helping detect conditions earlier and improve patient care worldwide.
The ISPOR International Annual Conference 2026 brings together global leaders in health economics and outcomes research to explore the future…
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Inflammatory Bowel Disease (IBD) management has evolved significantly with advanced therapies…
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction Earlier cancer detection remains one of the most powerful opportunities…
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction: COPD as a “Syndrome,” Not Just One Disease Chronic…
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction: A Silent Disease Becoming a Public Health Emergency Metabolic…
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Knowing When To Treat – AI for Transformation, Infection Risk, and…
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Early detection and personalised treatment in chronic lymphocytic leukaemia (CLL) remain…
By Léon Van Wouwe, Clinical Innovation Director, Volv Global A Hidden Cancer in Plain Sight Multiple myeloma (MM) has…
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction: The Urgency of Early Diagnosis in Type 1 Diabetes…
How AI-driven insights from RWD accelerate the diagnosis and treatment of undiagnosed patients: A case study in alpha-1 antitrypsin deficiency…